Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial

Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial Dr Amy E Colson, MDa,b Send email to acolson@challiance.org ∙ Princy N Kumar, MDc ∙ Peter J Ruane, MDd ∙ Ploenchan Chetchotisakd, MDe ∙ Winai Ratanasuwan, MDf ∙ Afaaf Liberty, MBChBg ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01442-X/abstract?dgcid=raven_jbs_etoc_feature_lancet